MetrioPharm AG was able to reach further goals with respect to the patent protection of MP1032. A far-reaching protection is a crucial factor for the out-licensing and marketing of our substance in the future. Our focus lies on the highly regulated pharmaceutical markets, therefore every patent is not only a proof of quality for our development, but also a crucial factor for value creation.
The European substance patent of MetrioPharm AG has been issued and published on May 7, 2014, as announced earlier by the European Patent Office. An important step towards granting was also achieved in the US market. In line with its initial positive evaluation, the United States Patent and Trademark Office now officially declared in a so-called "Notice of Allowance" the intention to grant a US patent. MetrioPharm AG is thus expecting the granting of the compound patent for the US market within the current year.
The patentability in the US market is a critical asset. Since 33% of the worldwide pharmaceutical sales rev-enue is generated in North America, this region is a priority market for the marketing and out-licensing of the MP1000 compound class.
Phase I – the next step
Since MetrioPharm AG was able to finalize the regulatory pharmacology and toxicology studies in the past months, all requirements for clinical studies are now fulfilled. The clinical trials are an important part in the drug development process, in which the efficacy and safety of the drug is going to be analyzed.
The upcoming clinical Phase I trial investigates the safety and characteristics of the compound in the hu-man organism. In this part of the clinical trial, the substance is tested in a small group of healthy volunteers. According to our company principles, the clinical Phase I trial will be conducted together with a specialized and experienced partner. First validations of the bioanalytical measurement methods necessary for these trials have already begun.
A successful completion of the Phase I trial will confirm the safety of our substance. Only with a positive result further tests on the efficacy in certain indications is possible. As MP1032 already achieved an out-standing safety profile in all preclinical tests, MetrioPharm AG is highly confident to obtain excellent results.
Annual General Meeting
This year's Annual General Meeting will take place on June 23, 2014 in Zurich. The annual report 2013 is available for download on our homepage since June 2, 2014.